News Medical on MSN10h
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...
PetHelpful on MSN15h
Can a Ketogenic Diet Destroy Your Dog's Cancer? Here's What a Vet Has to Say
The ketogenic diet has proven to be useful in mast cell tumors, but many other types of cancer need to be investigated. In ...
thecardiologyadvisor.com3d
FDA Extends Review of Elamipretide for Barth Syndrome
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
News Medical on MSN1d
Revolutionizing diabetes care with innovative targets and therapeutic options
A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...
Pharmabiz15d
GenSight Biologics announces publication of 5-year outcomes for patients treated unilaterally with Lumevoq gene therapy
the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due to a mutated ND4 mitochondrial gene. The patients had all participated in the phase III trials RESCUE and ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
Pharmabiz8d
Solid Biosciences’ AAV-based gene therapy candidate, SGT-212 for Friedreich’s ataxia receives US FDA fast track designation
Charlestown, Massachusetts Thursday, January 23, 2025, 15:00 Hrs [IST] ...
Daily Excelsior4h
Next industrial revolution will be driven by biotechnology and bio-economy: Dr Jitendra
Abhinav Singh In August 2024, the Union cabinet approved the BioE3 policy-Biotechnology for Economy, Environment and ...
Le Lézard2d
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene ...